Christopher David Ozeroff is CLO & VP at ARCA biopharma, Inc. (ABIO). They have made 1 open-market trade across 1 company since 2015, most recently 2021-11-22.
CIK 0001454996
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $226K since 2021, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ABIO | 50,970 | $122K |
Shares reported on the most recent Form 4, priced at the 2021-11-23 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ABIO | BUY | 2021-11-22 | 2021-11-23 | $2.26 | $226K | -5.4% | +2.3% | -18.1% |
| ABIO | SELL · 10b5-1 | 2017-04-04 | 2017-04-05 | $2.41 | $1K | -2.1% | +0.0% | -2.1% |
| ABIO | SELL · 10b5-1 | 2017-02-28 | 2017-03-01 | $2.61 | $1K | -3.9% | +0.0% | -3.9% |
| ABIO | SELL · 10b5-1 | 2016-09-20 | 2016-09-21 | $2.89 | $3K | -2.4% | -12.3% | -9.4% |
| ABIO | SELL · 10b5-1 | 2016-04-05 | 2016-04-06 | $3.52 | $1K | +1.9% | +4.2% | -14.2% |
| ABIO | SELL · 10b5-1 | 2016-03-01 | 2016-03-02 | $3.51 | $2K | +4.9% | -5.2% | -7.6% |
| ABIO | SELL · 10b5-1 | 2015-09-18 | 2015-09-21 | $6.32 | $7K | -24.1% | +0.9% | +0.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.